Ferric pyrophosphate citrate may play a role in the therapeutic armamentarium for dialysis patients.
On January 26, 2015, the FDA approved Rockwell Medical’s innovative iron delivery drug ferric pyrophosphate citrate (Triferic). The drug is indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. It is the only iron preparation delivered via dialysate. It has a safety profile similar to placebo. None of the more than 100,000 individual administrations of the drug resulted in anaphylaxis. Ferric pyrophosphate citrate has been shown to deliver sufficient iron to the bone marrow and maintain hemoglobin levels without increasing iron stores and while significantly decreasing the use of erythropoiesis-stimulating agents by 35%. The medication is expected to be commercially available this year.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.